Supplemental Annuity Collective Trust (SACT) of New Jersey’s Alexion Pharmaceuticals ALXN Stock Holding History

Supplemental Annuity Collective Trust (SACT) of New Jersey’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$919K	–	225
2021 Q2	$919K	Hold	5,000	–	–	0.3%	106
2021 Q1	$765K	Hold	5,000	–	–	0.27%	122
2020 Q4	$781K	Hold	5,000	–	–	0.29%	108
2020 Q3	$572K	Hold	5,000	–	–	0.24%	117
2020 Q2	$561K	Hold	5,000	–	–	0.26%	113
2020 Q1	$449K	Hold	5,000	–	–	0.25%	121
2019 Q4	$541K	Hold	5,000	–	–	0.22%	149
2019 Q3	$490K	Buy	+5,000	New	+$564K	0.22%	146

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Supplemental Annuity Collective Trust (SACT) of New Jersey's ALXN Position: Q3 2021 in Review

Supplemental Annuity Collective Trust (SACT) of New Jersey sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 5,000 shares — an estimated $919K sold.

Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $919K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Supplemental Annuity Collective Trust (SACT) of New Jersey reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Supplemental Annuity Collective Trust (SACT) of New Jersey sold 5,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $919K.
Supplemental Annuity Collective Trust (SACT) of New Jersey first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Supplemental Annuity Collective Trust (SACT) of New Jersey's Alexion Pharmaceuticals position peaked at $919K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Supplemental Annuity Collective Trust (SACT) of New Jersey's 13F filing for Q3 2021, filed 26 Oct 2021.